Table 1.

Effects of mirabegron on number of incontinence episodes per 24 hours

Parameter	Nitti et al43		Khullar et al44		Van Kerrebroeck et al45
	Placebo	Mirabegron 50 mg	Placebo	Mirabegron 50 mg	Placebo	Mirabegron 25 mg	Mirabegron 50 mg
Incontinence episodes per 24 hours (n)^
n	291	293	325	312	262	254	257
Baseline (mean)	2.67	2.83	3.03	2.77	2.43	2.65	2.51
Change from baseline (adjusted mean)†	−1.17	−1.57	−1.13	−1.47	−0.96	−1.36	−1.38
Difference from placebo (adjusted mean)†	–	−0.41	–	−0.34	–	−0.40	−0.42
95% confidence interval	–	(−0.72, −0.09)	–	(−0.66, −0.03)	–	(−0.74, −0.06)	(−0.76, −0.08)
P value		0.003#		0.026#		0.005#	0.001#

Notes:

^‡Week 12 is last observation on treatment;

^†least squares mean adjusted for baseline, gender, and geographical region;

^{^}for incontinence episodes per 24 hours, the analysis population is restricted to patients with at least one episode of incontinence at baseline;

^#statistically significantly superior compared to placebo at the 0.05 level with multiplicity adjustment. Data from Mirabegron prescribing information.48